SynthesisFrontiers in nutrition2026
Nutraceuticals for the management of weight and inflammation-related complications in obesity: a pediatric perspective. Systematic review and network meta-analysis.
Synthesis in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Obesity, defined as excess body fat that impairs health, is a major public health challenge associated with metabolic and inflammation-related complications across the lifespan. Conventional treatments often show limited long-term efficacy, leading to growing interest in complementary strategies. Nutraceuticals have been studied for their potential in weight management and metabolic improvement. This systematic review and network meta-analysis evaluates the role of nutraceuticals in obesity management, with attention also given to pediatric populations. Methods: We performed a systematic review and network meta-analysis (NMA) following Cochrane and PRISMA-NMA 2020 guidelines. Eligible randomized and non-randomized trials enrolled children or adults with overweight/obesity, testing nutraceuticals (inulin, butyrate, long-chain omega-3 fatty acids, vitamin B, carnitine) versus placebo or standard care. Primary outcomes included anthropometric, metabolic, and inflammatory markers. The protocol was registered in PROSPERO (ID: CRD420251151333). Results: L-carnitine emerged as the most effective and consistent intervention, producing significant reductions in body weight, body mass index (BMI), waist circumference, fasting blood glucose, Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), and LDL-Cholesterol (LDL-C), along with a significant increase in HDL-Cholesterol (HDL-C). Inulin and long-chain omega-3 fatty acids (LC n3-PUFA) exhibited modest or non-significant effects on most outcomes, although LC n3-PUFA significantly reduced triglyceride levels. Butyrate demonstrated beneficial effects on BMI and waist circumference in children, whereas vitamin B showed limited impact. Dose-response analyses confirmed the efficacy of L-carnitine at relatively low dosages, while other supplements required higher intakes without achieving the predefined clinical targets. Conclusion: This NMA shows heterogeneous effects of nutraceuticals on obesity-related outcomes. L-carnitine emerged as the most consistent intervention, while LC n3-PUFA, inulin, butyrate, and vitamin B provided more limited benefits. Preliminary evidence suggests potential age-related differences, highlighting the need for further studies to define age-specific and tailored strategies for obesity management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.